T细胞接合剂(TCE)研究进展
摘要
关键词
全文:
PDF参考
[1]Baumeister SH, Freeman GJ,Dranoff G, Sharpe AH.Coinhibitory pathways in immunotherapy for cancer.Annu Rev Immunol.2016;34:539–73.
[2]June CH,Connor RSO,Kawalekar OU,Ghassemi S,Milone MC.CAR T cell immunotherapy for human cancer.Science.2018;359:1361–5.
[3]Goebeler M,Bargou RC.T cell-engaging therapies—BiTEs and beyond.Nat Rev Clin Oncol. 2020;17:418–34.
[4]Sebestyen Z,Prinz I,Dechanet-Merville J, Silva-Santos B,Kuball J.Translating gammadelta (gammadelta)T cells and their receptors into cancer cell therapies.Nat Rev Drug Discov.2020; 19:169–84.
[5]Zhao Y,Aldoss I,Qu C,Crawford JC,Gu Z, Allen EK,et al.Tumor-intrinsic and-extrinsic determinants of response to blinatumomab in adults with BALL.Blood.2021;137:471–84.
[6]Nair-Gupta P,Diem M,Reeves D,Wang W, Schulingkamp R,Sproesser K,et al.A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia. Blood Adv.2020;4:906–19.
[7]Sharma,P.et al.Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032):a multicentre,open-label,two-stage,multi-arm,phase 1/2 trial.Lancet Oncol. 17,1590–1598(2016).
[8]Kao,H.-F.&Lou,P.-J.Immune checkpoint inhibitors for head and neck squamous cell carcinoma:current landscape and future directions.Head Neck 41,4–18(2019).
[9]Yamamoto K,Venida A,Yano J,Biancur DE, Kakiuchi M,Gupta S,et al.Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I.Nature.2020;581:100–5.
[10]Einsele H,Borghaei H,Orlowski RZ, Subklewe M,Roboz GJ,Zugmaier G,et al.The BiTE (bispecific T-cell engager)platform:development and future potential of a targeted immuno-oncology therapy across tumor types.Cancer-Am Cancer Soc.2020;126:3192–201.
Refbacks
- 当前没有refback。